ciation (AHA) convened a writing committee. The ACCF and AHA adhere to a rigorous policy
regarding relationships with industry and other entities (RWI) of authors and peer reviewers …

Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine‐
5′‐diphosphate (ADP)‐mediated platelet aggregation in vivo. These compounds are …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

The aim of the current study is to identify the human cytochrome P450 (P450) isoforms
involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Clinical efficacy of the antiplatelet drug clopidogrel is hampered by its variable
biotransformation into the active metabolite,. The variability in the clinical response to …

Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated
with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has …

In the normal course of the delivery of care, anesthesiologists encounter many patients who
are receiving drugs that affect platelet function as a fundamental part of primary and …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …